Cyteir Therapeutics Inc. is trying to curb the growth of chronic lymphocytic leukemia by blocking the repair of DNA damage. The company's small molecule hits a critical step in a DNA repair pathway that is overactive in about 40% of CLL patients.

DNA repair involves a series of enzymatic cuts and stitches to DNA molecules that become frayed as a result of mutation, radiation or chemically induced damage.